HomeAbout UsScienceNewsroomCareersContact
中文 EN
About Us
Science
Newsroom
Careers
Contact中文 EN
Press Releases
View all
Qihan Biotech announces the completion of pre-Series B financing for developing stem cell-derived cell therapy products with high-throughput multiplexable genome editing
September 2023
Hangzhou Qihan Biotech Co., Ltd. today announced the successful completion of a pre-Series B financing exceeding $16 million.
Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND) Application for QN-019a, a Multi-locus Gene-Editing Cell Therapy Product to treat CD19-positive B-Cell Lymphoma
July 2023
Qihan Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2022
April 2022
NK cells derived from genetically engineered human induced pluripotent stem cells (iPSCs) hold great potential to become the next generation allogeneic cell therapy products.
Media Coverage
View all
Eyeing organs for human transplants, companies unveil the most extensively gene-edited pigs yet
December 2019
Science
The Bloomberg 50
November 2017
Bloomberg
Luhan Yang, Qihan Biotech: In the name of science, reverence for the greatness of life
May 2021
Sequoia
Publications
View all
Extensive germline genome engineering in pigs
September 2020
Nat Biomed Eng
Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9
June 2017
Science
RNA-guided human genome engineering via Cas9
January 2013
Science
浙ICP备18027606号-1
Copyright © 2018-2023
About Us
Our Story
Leadership
Investors
Science
Technology
Products
Newsroom
Press ReleaseMedia CoveragePublications
Careers
Our Values
Our Culture
Job Openings
Contact
info@qihanbio.commedia@qihanbio.comcareers@qihanbio.com
浙ICP备18027606号-1
Copyright © 2018-2023